MP-18 Assessment of the alignment between research funding allocation and consensus research priority areas in kidney cancer
01/01/70 from 21:45 to 22:15
TBD
Presenter

Steven SL Lu, Canada

Medical Student

Cumming School of Medicine

University of Calgary

Abstract

Assessment of the alignment between research funding allocation and consensus research priority areas in kidney cancer

Steven Lu1, Jeenan Kaiser2, Michael A. Jewett3, Daniel Y.C. Heng4, Nimira Alimohamed4, Bimal Bhindi5.

1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; 2Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; 3Department of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada; 4Tom Baker Cancer Centre , University of Calgary Cumming School of Medicine, Calgary, AB, Canada; 5Section of Urology, Department of Surgery, University of Calgary, Cumming School of Medicine, Calgary, AB, Canada

Introduction: Finite resources are available to fund research, and it is important to ensure stakeholder input is identified and prioritized. In this light, the KCRNC and CIHR sponsored a consensus-based priority-setting partnership that brought together a group of patients, caregivers, and clinicians to identify the top 10 research priorities in kidney cancer (Table), with a consensus document published in 2017.[1][2] We sought to determine how research funding allocation has aligned with these previously identified priority areas. 

Methods: We queried publicly available Canadian and American research databases to identify all research funds allocated to kidney cancer from 2018-2020. Each funded project was assessed to determine which priority areas were addressed. We evaluated the percent of projects and percent of funding dollars (converted to CAD) allocated to priority areas. Descriptive statistics were used.

Results: A total of 121 kidney cancer research projects were funded between 2018-2020, with 15 Canadian projects (total $ = 2,421,126 CAD) and 106 American projects (total $ = 71,523,080 CAD). Half (50%) of the projects focused on localized cancer while 26% of projects focused on metastatic kidney cancer. Overall, 49% of projects aligned to one priority area, 47% of projects aligned to multiple priority areas, and 4% of projects were not aligned to priority areas.  The priority areas which received the most funding were causes of kidney cancer (priority #10, 64% of funds), biomarkers (priorities #1b+1c+5, 59%), and immunotherapies (priority #4, 41%)(Table). Unfunded priority areas were supportive care (priority #6) and the role of biopsy in kidney cancer management (priority #8).

Conclusion: Nearly all kidney cancer projects funded since 2018 were aligned with one or multiple stakeholder-identified research priority areas, although some priority areas remain underfunded. Mechanisms to improve distribution of funding to all priority areas may be warranted. 

References:

[1] Jones J, Bhatt J, Avery J, et al. The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians. Can Urol Assoc J 2017 Dec;11(12):379-387. DOI: 10.5489/cuaj.4590.
[2] Jones JM, Bhatt J, Avery J, et al. Setting Research Priorities for Kidney Cancer. European Urology. 2017 Dec;72(6):861-864. DOI: 10.1016/j.eururo.2017.04.011.


© 2022 CUA 74th Annual Meeting